Want to join the conversation?
$VRTX continues to expect 2016 combined non-GAAP research and development as well as selling, general and administrative expenses to be in range of $1.18-1.23Bil. The forecast excludes stock-based compensation expense and certain other expenses.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.